Mary Kennedy and GSK Ireland launch Respiratory Syncytial Virus (RSV) awareness campaign encouraging over 65s and at-risk ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...

Speaking about the low awareness of RSV risk for over 65s, Prof Patrick Mitchell, Consultant Respiratory Physician at Trinity ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

Settlement resolves 80,000 or 93% of pending US cases GSK top gainer on FTSE-100, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Oct 10 (Reuters) - GSK (GSK.L ...

GSK GSK1.11%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...

Broadcaster and writer Mary Kennedy has partnered with GlaxoSmithKline (GSK) Ireland to launch a new public awareness campaign highlighting the signs, symptoms and risk factors of Respiratory ...

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

Ignoring symptoms can lead to pneumonia and in some cases even hospitalisation for those particularly vulnerable ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...